Heartworm Prevention in Border Collies — HDU Science and Choosing the Right Drug
Every spring, veterinary clinics across southern Japan see an uptick in calls: “Is it time to start heartworm prevention?” The answer is both yes — and nuanced. When to begin isn’t a matter of habit; it can be calculated scientifically. And for Border Collie owners, there’s an additional variable to understand: the relationship between ABCB1 gene mutations (MDR1) and prevention drug selection.
This article walks through the science of heartworm transmission risk, provides climate data specific to Kagoshima Prefecture, and reviews the safety profile of prevention drugs in the context of Border Collie genetics.
What Is Heartworm Disease?
Heartworm disease is caused by Dirofilaria immitis, a parasitic roundworm transmitted through mosquito bites. When a mosquito feeds on an infected dog, it ingests microfilariae (L1 larvae) circulating in the bloodstream. These larvae develop through two molts inside the mosquito, reaching the infective L3 stage — a process that requires a daily average temperature above 14°C (57°F).
From Mosquito to Heart: The Lifecycle
| Time After Infection | Parasite Status |
|---|---|
| Day 0–3 | L3 larvae deposited under skin; migrate through subcutaneous tissue |
| ~Day 65 | Molted to L5 (pre-adult) stage |
| ~Day 100 | Arrival in the heart and pulmonary arteries |
| 6–7 months post-infection | Sexual maturity; microfilariae released into bloodstream |
Adult worms measure 15–18 cm (6–7 in) in males and 25–31 cm (10–12 in) in females. They reside primarily in the pulmonary arteries and right ventricle, causing proliferative endarteritis, pulmonary vascular remodeling, and pulmonary hypertension.
What Happens Without Treatment
Mild infections may produce nothing more than a chronic cough or exercise intolerance. As worm burden increases, chronic right-sided heart failure develops. The most severe presentation is vena caval syndrome: massive worm burden extends from the pulmonary artery retrograde into the right atrium and caudal vena cava, causing tricuspid regurgitation, cardiogenic shock, hepatic failure, renal failure, and hemoglobinuria. The case fatality rate without emergency surgical removal is high (Simón et al., Clinical Microbiology Reviews, 2012).
Prevention is by far the more rational intervention.
HDU — Calculating Infection Season Scientifically
“Start prevention in April” is a commonly heard heuristic in Japan. The science behind it is the Heartworm Development Unit (HDU) model.
The Formula
Daily HDU = Daily Mean Temperature (°C) − 14
(Negative values treated as 0)The heartworm larva requires a cumulative HDU of 130 or more to mature to the infective L3 stage inside the mosquito. When accumulated HDUs cross this threshold in a given region, heartworm transmission becomes possible (Fortin & Slocombe, as cited in American Heartworm Society methodology documentation).
Kagoshima City: Monthly Climate Data
Based on Japan Meteorological Agency 30-year normals (1991–2020, Kagoshima Station):
| Month | Mean Temp (°C / °F) | Daily HDU | Monthly HDU (approx.) |
|---|---|---|---|
| January | 8.7 / 47.7 | 0 | 0 |
| February | 9.9 / 49.8 | 0 | 0 |
| March | 12.8 / 55.0 | 0 | 0 |
| April | 17.1 / 62.8 | 3.1 | ~93 |
| May | 21.0 / 69.8 | 7.0 | ~217 |
| June | 24.0 / 75.2 | 10.0 | ~300 |
| July | 28.1 / 82.6 | 14.1 | ~437 |
| August | 28.8 / 83.8 | 14.8 | ~459 |
| September | 26.3 / 79.3 | 12.3 | ~369 |
| October | 21.6 / 70.9 | 7.6 | ~236 |
| November | 16.2 / 61.2 | 2.2 | ~66 |
| December | 10.9 / 51.6 | 0 | 0 |
Source: Japan Meteorological Agency, Kagoshima Observing Station (1991–2020 normals)
Kagoshima’s Transmission Season (15-Year Data)
Meiji Animal Health’s 15-year retrospective analysis of HDU data for Kyushu and Okinawa shows the following for the Kagoshima area:
- Transmission begins: around April 19 (cumulative HDU exceeds 130)
- Transmission ends: around November 21 (rolling 30-day HDU falls below 130)
The standard veterinary guideline — “begin one month after mosquitoes appear; end one month after they disappear” — translates to a recommended administration window of May through December (8 months) for the Kagoshima region (Meiji Animal Health, HDU Regional Dataset: Kyushu/Okinawa).
Scheduling a veterinary visit in April to complete pre-season testing and receive a prescription positions owners to begin May administration without delay.
Border Collies and ABCB1 Mutations — What the Data Actually Shows
Discussions of MDR1 (ABCB1) mutations in dogs often conflate Border Collies with rough Collies or Australian Shepherds. The actual data tells a different story.
The Role of P-Glycoprotein
The ABCB1 gene encodes P-glycoprotein (P-gp), a drug efflux pump that protects the central nervous system by preventing toxin and drug accumulation at the blood-brain barrier. When P-gp function is lost or reduced through mutation, macrocyclic lactones (MLs) and other P-gp substrates accumulate in the brain, causing neurotoxicity.
The Classic 4bp Deletion (c.227_230delATAG)
The most studied ABCB1 mutation is a 4-base pair frameshift deletion. Breed distribution data from Washington State University’s Program in Individualized Medicine (PrIMe) and the landmark 2004 Neff et al. study in PNAS shows:
| Breed | Mutation Frequency |
|---|---|
| Rough/Smooth Collie | ~70% |
| Australian Shepherd | ~50% |
| Shetland Sheepdog | ~15% |
| German Shepherd Dog | ~10% |
| Border Collie | <5% (often <1% in tested populations) |
For Japanese Border Collies specifically, Mizukami et al. (Journal of Veterinary Diagnostic Investigation, 2012) found the 4bp deletion carrier rate to be 0.49%, with a variant allele frequency of just 0.25% in domestic Border Collies. Treating Border Collies as equivalent to rough Collies in this regard is not supported by population data.
A Different ABCB1 Variant Common in Japanese Border Collies
However, a separate ABCB1 variant exists at notably higher frequency in Japanese Border Collie populations. Yabuki et al. (BMC Veterinary Research, 2013) analyzed 472 Border Collies in Japan and found the following for the c.-6-180T>G promoter region variant:
- Wild-type (T/T): 60.0%
- Heterozygous (T/G): 30.3%
- Homozygous variant (G/G): 9.8%
- Variant G allele frequency: 24.9%
In total, 40.1% of the cohort carried at least one variant allele. This variant has a demonstrated association with phenobarbital-resistant epilepsy in Border Collies. Its clinical significance with respect to macrocyclic lactone heartworm preventives is currently under-researched — no definitive evidence establishes increased risk at prevention doses, but this is not the same as proven safety at all doses for all individuals.
Additionally, a rare novel insertion mutation (AAT insertion between positions 72–73) was identified in a Border Collie that showed ivermectin-associated depression and salivation — neither the classic deletion nor the c.-6-180T>G variant (Sato et al., PMC2998746, 2010).
The ABCB1 picture in Border Collies is this: the classic deletion conferring high ivermectin sensitivity is rare (<1%); a different promoter variant is common (~40%); and its interaction with prevention-dose MLs remains an active area of investigation. Genetic testing is the most direct way to characterize an individual dog’s ABCB1 status.
Prevention Drug Options and Safety Profiles
Macrocyclic lactone (ML) compounds are the backbone of heartworm prevention. Understanding their mechanism and relative safety margins clarifies what “safe for MDR1 mutation dogs” actually means.
How MLs Work
MLs bind to glutamate-gated chloride channels (GluCl) in invertebrate neurons, causing irreversible hyperpolarization and paralysis of heartworm larvae. In mammals, P-gp at the blood-brain barrier normally effluxes MLs before significant CNS accumulation can occur — the basis for their wide therapeutic index in wild-type animals.
Safety Data by Drug Class
Compiled from Mealey & Meurs (Journal of the American Veterinary Medical Association, 2008) and Merola & Eubig (Veterinary Clinics of North America, 2012):
| Active Ingredient | Prevention Dose | Safety in MDR1 Homozygous Dogs | Notes |
|---|---|---|---|
| Ivermectin | 6–12 µg/kg/month | Safe at prevention doses | Neurological risk begins at ~100 µg/kg oral |
| Milbemycin oxime | 0.5 mg/kg/month | Safe (adverse effects at ≥5 mg/kg) | Most commonly prescribed in Japan |
| Moxidectin (oral, monthly) | 3 µg/kg/month | Safe | 6-month injectable is contraindicated* |
| Selamectin (topical) | 6–12 mg/kg/month | Safest profile (no effect at 40 mg/kg spot-on) | Topical application only |
*Moxidectin 6-month sustained-release injectable (ProHeart 6/12) has been associated with acute, potentially fatal neurotoxicity in sensitive breeds (rough Collies, Australian Shepherds). It should be avoided in any breed with suspected P-gp impairment.
At labeled prevention doses, all oral/topical ML products are considered safe even in classic ABCB1-1Δ homozygous dogs by the available evidence. Where uncertainty exists — particularly regarding the c.-6-180T>G variant — initiating a new product under veterinary supervision with observation for adverse effects is the prudent approach.
Why Monthly Dosing Works: Retrospective Efficacy
MLs clear from the body within days of administration. Their preventive effect rests on retrospective (lookback) efficacy: when administered within 30–60 days of infection, MLs eliminate the L3 and L4 larvae already present in the host. Monthly dosing ensures larvae from the preceding 30-day exposure window are cleared before they can mature further.
Moxidectin’s high lipophilicity and extended half-life (13.9–25.9 days) confer particularly robust retrospective efficacy, demonstrated at 60+ days post-infection in controlled trials (Bowman et al., Veterinary Parasitology, 2012; Rehbein et al., Parasites & Vectors, 2022).
Before Starting Prevention: Why Blood Testing Is Non-Negotiable
Initiating heartworm prevention without prior testing carries real risk.
The Risk of Treating an Infected Dog
If a dog harboring significant microfilaremia receives a microfilaricidal dose of prevention medication — particularly milbemycin oxime — the rapid die-off of circulating microfilariae can trigger anaphylaxis-like reactions, vascular obstruction, circulatory shock, and death. This is a preventable iatrogenic event.
Furthermore, adult worms are not killed by ML preventives. An undetected active infection that goes untreated allows adults to live for 5–7 years, accumulating further cardiac and vascular damage.
Why Both Tests Are Required
The 2024 American Heartworm Society (AHS) Canine Guidelines recommend both antigen testing and microfilaria testing annually. The rationale:
- Antigen tests can give false negatives: Immune complex formation can mask antigen detection, particularly in low-worm-burden or single-sex infections
- Occult infections are common: More than 20% of infected dogs are amicrofilaremic (males only, or immune-mediated microfilarial clearance), making microfilaria tests alone insufficient
- Detection window: Antigen tests become positive only ~7 months post-infection; a recently infected dog can test negative
The AHS 2024 guidelines also note that year-round administration, rather than seasonal, reduces the risk of missed doses and the diagnostic ambiguity that comes with lapsed prevention.
Life Stage Considerations
Puppies
Most products are approved from 6–8 weeks of age. Heartworm testing is not meaningful before 7 months of age (the minimum time for antigen or microfilaria to be detectable post-infection). The recommended first test occurs 6–7 months after starting prevention.
Vertical transmission (transplacental or transmammary) of D. immitis is not established; puppies are not born infected. However, outdoor exposure to mosquitoes means risk begins early in endemic regions.
Adults on Continuous Prevention
Annual dual testing (antigen + microfilaria) should be maintained regardless of continuous administration history. Year-round prevention is the recommended standard in high-transmission regions like Kagoshima.
Senior Dogs
Older dogs with declining hepatic or renal function warrant pre-treatment blood panels, as MLs undergo hepatic metabolism and renal excretion. “Stopping prevention due to age” is not supported by evidence — older dogs face elevated infection risk due to immunosenescence, and the cardiovascular consequences of infection in geriatric patients are disproportionately severe (Kealy et al., Veterinary Surgery, 2013).
When Prevention Fails — And When It Doesn’t
The most common reason prevention medications fail is inconsistent administration rather than pharmacological failure. Irregular dosing creates gaps in retrospective coverage, allowing larvae that survived the window to mature.
The AHS 2024 guidelines explicitly endorse year-round prevention as superior to seasonal dosing specifically because of improved compliance — fewer opportunities for owners to forget. If monthly administration is logistically difficult, discussing a year-round protocol or calendar reminders with a veterinarian is the most practical intervention.
When a prevention-apparent failure does occur — breakthrough infection in a dog documented as receiving prevention — the treating veterinarian should notify the product manufacturer and the AHS, as these cases contribute to pharmacovigilance data.
Prevention depends on regular dosing, confirmed ingestion, and annual testing. Keep records, and ask a veterinarian before waiting for the next scheduled dose when something goes wrong.
About ROSCH KENNEL: A Border Collie specialist breeder located in the Kirishima highlands of Kagoshima, Japan, at an elevation of 750 m (2,460 ft). All breeding dogs undergo a panel of 15+ genetic tests, including ABCB1 screening, with results published openly. Early Neurological Stimulation (ENS) is implemented with every litter.
References
- Simón F, Siles-Lucas M, Morchón R, González-Miguel J, Mellado I, Carretón E, et al. Human and Animal Dirofilariasis: the Emergence of a Zoonotic Mosaic. Clinical Microbiology Reviews. 2012;25(3):507–44.
- Nakagaki K, Yoshida M, Nogami S, Nakagaki K. Prevalence of Dirofilaria immitis infection among shelter dogs in Tokyo, Japan, after a decade. Parasite. 2014;21:4. PMC3937804.
- Neff MW, Robertson KR, Wong AK, et al. Breed distribution and history of canine mdr1-1Δ, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proceedings of the National Academy of Sciences. 2004;101(32):11725–30.
- Mizukami K, Chang HS, Yabuki A, et al. Rapid genotyping assays for the 4-base pair deletion of canine MDR1/ABCB1 gene and low frequency of the mutant allele in Border Collies. Journal of Veterinary Diagnostic Investigation. 2012;24(1):127–34. PubMed:22362942.
- Yabuki A, Mitani S, Fujiki M, et al. Comparative study of variant ABCB1 in dog breeds in Japan. BMC Veterinary Research. 2013;9:232. PMC3834651.
- Sato M, Satoh H, Aotsuka T, Saito H, Harasawa R. Novel insertion mutation of the ABCB1 gene associated with ataxia in a Border Collie dog. Journal of Veterinary Medical Science. 2010;72(11):1527–9. PMC2998746.
- Mealey KL, Meurs KM. Breed distribution of the ABCB1-1Δ (multidrug sensitivity) polymorphism among dogs undergoing ABCB1 genotyping. Journal of the American Veterinary Medical Association. 2008;233(6):921–4.
- Merola VM, Eubig PA. Toxicology of avermectins and milbemycins (macrocyclic lactones) and the role of P-glycoprotein in dogs and cats. Veterinary Clinics of North America: Small Animal Practice. 2012;42(2):313–33. PMC4152460.
- Bowman DD, Atkins CE. Heartworm biology, treatment, and control. Veterinary Clinics of North America: Small Animal Practice. 2009;39(6):1127–58.
- American Heartworm Society. 2024 Canine Heartworm Guidelines. heartwormsociety.org/veterinary-resources.
- Japan Meteorological Agency. Kagoshima Station 30-Year Normals (1991–2020). data.jma.go.jp.
- Meiji Animal Health. HDU-Based Heartworm Transmission Period Data: Kyushu/Okinawa Region. filaria.jp.
Daily observation is where the next article begins.
Instagram shows the dogs in daily life. The journal turns the themes we notice there into evidence-aware resources.